文献速递糖尿病肥胖与代谢综合征

肠促胰岛素与心血管系统:连接消化与代谢

Incretins and the cardiovascular system: bridging digestion with metabolism.
PubMed 文献 · Lancet Diabetes Endocrinol · 2025-07-07

本文提出肠促胰岛素激素——胰高血糖素样肽-1(GLP-1)和葡萄糖依赖性促胰岛素肽(GIP)——是连接消化、代谢与心血管功能的关键环节,支持机体对营养摄入的生理适应。这些激素通过一氧化氮促进血管舒张、改善内皮功能与血压控制,GLP-1还有轻度正性肌力作用,并具有抗炎和抗氧化效应。临床上GLP-1受体激动剂和GLP-1/GIP双受体激动剂利用这些效应改善2型糖尿病或肥胖患者的心血管结局,并可能改善肾脏结局。

要点

  • 肠促胰岛素激素连接消化、代谢与心血管功能,支持营养摄入的生理适应。
  • 肠促胰岛素通过一氧化氮促进血管舒张,改善内皮功能、血管弹性和血压控制。
  • GLP-1受体激动剂和GLP-1/GIP双受体激动剂改善2型糖尿病或肥胖患者心血管结局,可能改善肾脏结局。

核心结论

  • 肠促胰岛素激素是连接消化、代谢与心血管功能的关键环节,基于肠促胰岛素的治疗不仅调节血糖,还帮助降低发病率和死亡率,正成为现代糖尿病管理的核心组成部分。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • 餐后肠促胰岛素激素通过一氧化氮促进血管舒张,尤其在内脏和外周循环,改善内皮功能、血管弹性和血压控制,支持组织灌注并满足机体增加的代谢需求。
  • GLP-1具有轻度正性肌力作用,促进有效循环而不增加心脏负担;血管舒张增强葡萄糖和脂质摄取,将消化直接与能量代谢联系起来。
  • 这些机制降低血管阻力、减少心脏负荷、改善心肌葡萄糖利用,在缺血事件期间尤其有价值。
  • 肠促胰岛素还具有抗炎和抗氧化效应,有助于预防内皮功能障碍和动脉僵硬,降低动脉粥样硬化风险。
  • 临床上GLP-1受体激动剂和GLP-1/GIP双受体激动剂利用这些效应改善2型糖尿病或肥胖患者的心血管结局,并可能改善肾脏结局。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The mechanisms driving the cardiovascular and renal benefits of therapies targeting intestinal hormones in type 2 diabetes are still not fully understood. We propose that incretin hormones-glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP)-act as a critical link connecting digestion, metabolism, and cardiovascular function, supporting physiological adaptations to nutrient intake. Incretin hormones help regulate blood flow and cardiac activity, enhancing nutrient absorption while protecting the heart and vessels. After meals, incretin hormones promote vasodilation-especially in the splanchnic and peripheral circulations-via nitric oxide, improving endothelial function, vascular flexibility, and blood pressure control, which supports tissue perfusion and meets the body's increased metabolic demands. GLP-1 also has mild inotropic effects, promoting efficient circulation without straining the heart. At the same time, vasodilation boosts glucose and lipid uptake, linking digestion directly to energy metabolism. These mechanisms lower vascular resistance, reduce cardiac workload, and improve myocardial glucose use, which becomes especially valuable during ischaemic events. Incretins also have anti-inflammatory and antioxidant effects, which help prevent endothelial dysfunction and arterial stiffening, reducing the risk of atherosclerosis. Clinically, GLP-1 receptor agonists and dual GLP-1 and GIP receptor agonists leverage these effects to improve cardiovascular and possibly renal outcomes in people with type 2 diabetes or obesity. By linking digestion, metabolism, and cardiovascular health, incretin-based therapies do more than just regulate blood sugar; they help reduce morbidity and mortality and are becoming a core component of modern diabetes care.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Avogaro A, Fadini GP. Incretins and the cardiovascular system: bridging digestion with metabolism. Lancet Diabetes Endocrinol. 2025. PMID: 40639391. doi:10.1016/S2213-8587(25)00166-4

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。